[{"id":"2a09abe0-6495-491d-a75a-5fe8da47ac10","acronym":"","url":"https://clinicaltrials.gov/study/NCT04086485","created_at":"2021-01-18T20:00:12.098Z","updated_at":"2025-02-25T12:27:19.621Z","phase":"Phase 1/2","brief_title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","source_id_and_acronym":"NCT04086485","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["BRCA • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-24"},{"id":"a1840621-8a5b-4574-b0a3-08c3755470ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05680675","created_at":"2023-01-11T14:59:16.865Z","updated_at":"2025-02-25T16:39:35.915Z","phase":"","brief_title":"Dual-Tracer Theranostic PET","source_id_and_acronym":"NCT05680675","lead_sponsor":"University of Utah","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 06/04/2024","primary_completion_date":" 06/04/2024","study_txt":" Completion: 06/04/2024","study_completion_date":" 06/04/2024","last_update_posted":"2025-02-06"},{"id":"449ed9d2-cfb9-4804-ab05-1adc2070268b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122610","created_at":"2023-11-08T22:13:11.239Z","updated_at":"2025-02-25T16:47:11.811Z","phase":"Phase 1","brief_title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","source_id_and_acronym":"NCT06122610","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-05"},{"id":"77bffc42-2b22-4b22-8139-b83130b4cbfe","acronym":"COMPOSE","url":"https://clinicaltrials.gov/study/NCT04919226","created_at":"2021-06-10T01:52:29.850Z","updated_at":"2025-02-25T17:37:09.573Z","phase":"Phase 3","brief_title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","source_id_and_acronym":"NCT04919226 - COMPOSE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-01-29"},{"id":"b02d7446-9c2e-44de-aefb-87c2ab738292","acronym":"DOMINO START","url":"https://clinicaltrials.gov/study/NCT04081701","created_at":"2021-01-18T19:59:05.539Z","updated_at":"2025-02-25T15:43:40.367Z","phase":"Phase 4","brief_title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","source_id_and_acronym":"NCT04081701 - DOMINO START","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 12/31/2038","primary_completion_date":" 12/31/2038","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-12-19"},{"id":"8958a804-5b40-4f07-97d2-e49b0ff21eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946305","created_at":"2021-06-30T17:54:27.285Z","updated_at":"2024-07-02T16:34:25.830Z","phase":"","brief_title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","source_id_and_acronym":"NCT04946305","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 07/08/2024","primary_completion_date":" 07/08/2024","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-06-14"},{"id":"9236ed5b-4e48-4482-beb7-c4a2d4ec1f1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05844332","created_at":"2023-05-06T15:04:24.810Z","updated_at":"2024-07-02T16:34:27.152Z","phase":"","brief_title":"LUTATHERA Injection General Use Result Survey","source_id_and_acronym":"NCT05844332","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"076eece4-6905-454a-8a07-8b842556ea06","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595460","created_at":"2022-10-27T15:58:19.568Z","updated_at":"2024-07-02T16:35:01.901Z","phase":"Phase 1","brief_title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","source_id_and_acronym":"NCT05595460","lead_sponsor":"RayzeBio, Inc.","biomarkers":" PD-L1 • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["PD-L1 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-22"},{"id":"43f7cc62-ef83-45a1-96af-aa42f66b3905","acronym":"EXPLLN21-01","url":"https://clinicaltrials.gov/study/NCT05160480","created_at":"2021-12-16T13:53:37.371Z","updated_at":"2024-07-02T16:35:04.774Z","phase":"","brief_title":"A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG","source_id_and_acronym":"NCT05160480 - EXPLLN21-01","lead_sponsor":"University of California, Davis","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 9","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-05-09"},{"id":"3dd674e6-b496-4d73-a6b8-026abbece6f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05142696","created_at":"2021-12-02T15:53:46.962Z","updated_at":"2024-07-02T16:35:06.048Z","phase":"Phase 1/2","brief_title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","source_id_and_acronym":"NCT05142696","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 05/05/2025","primary_completion_date":" 05/05/2025","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2024-05-03"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"6523da63-b637-4812-96ab-2a31d0bd247c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05111509","created_at":"2021-11-08T14:53:10.714Z","updated_at":"2024-07-02T16:35:07.486Z","phase":"Phase 1","brief_title":"A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent","source_id_and_acronym":"NCT05111509","lead_sponsor":"Yusuf Menda","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 20","initiation":"Initiation: 08/22/2022","start_date":" 08/22/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-25"},{"id":"f51f49cf-f0c9-4ddc-b426-bcb5de14fa69","acronym":"","url":"https://clinicaltrials.gov/study/NCT04888481","created_at":"2021-05-17T18:56:01.878Z","updated_at":"2024-07-02T16:35:08.494Z","phase":"Phase 2","brief_title":"68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors","source_id_and_acronym":"NCT04888481","lead_sponsor":"University of Alberta","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-04-22"},{"id":"23956507-6f6e-456a-86d1-530788914d8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410743","created_at":"2022-06-08T11:58:16.092Z","updated_at":"2024-07-02T16:35:09.466Z","phase":"Phase 1","brief_title":"Evaluatioon of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors","source_id_and_acronym":"NCT05410743","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" SSTR • FAP","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR • FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-LNC1010"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-16"},{"id":"37ae51b7-8ad9-4388-90cd-0f703c6c8ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03145857","created_at":"2021-01-18T15:30:16.237Z","updated_at":"2024-07-02T16:35:21.781Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use","source_id_and_acronym":"NCT03145857","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-01-30"},{"id":"abe95a5f-8246-429d-92a8-a73471011fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01876771","created_at":"2021-01-18T08:24:57.554Z","updated_at":"2024-07-02T16:35:21.860Z","phase":"Phase 2","brief_title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","source_id_and_acronym":"NCT01876771","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/29/2014","start_date":" 04/29/2014","primary_txt":" Primary completion: 12/01/2033","primary_completion_date":" 12/01/2033","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2024-01-30"},{"id":"5cfe778d-fe5e-47ad-9d92-bcdc82f98727","acronym":"SORENTO","url":"https://clinicaltrials.gov/study/NCT05050942","created_at":"2021-09-21T11:53:31.080Z","updated_at":"2024-07-02T16:35:22.027Z","phase":"Phase 3","brief_title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","source_id_and_acronym":"NCT05050942 - SORENTO","lead_sponsor":"Camurus AB","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 332","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-26"},{"id":"83a011cc-3ed7-453f-8d6a-4bfef59bfc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583528","created_at":"2021-01-18T17:37:43.597Z","updated_at":"2024-07-02T16:35:22.583Z","phase":"","brief_title":"DOTATOC PET/CT for Imaging NET Patients","source_id_and_acronym":"NCT03583528","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-23"},{"id":"9b57d37c-e026-4d38-945c-c39b0746e939","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840149","created_at":"2021-02-11T16:53:15.299Z","updated_at":"2024-07-02T16:35:26.204Z","phase":"Phase 3","brief_title":"SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors","source_id_and_acronym":"NCT02840149","lead_sponsor":"Jewish General Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2023-12-14"},{"id":"2ce71cc8-c99e-442e-ada8-43ed288e9bdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06121271","created_at":"2023-11-07T16:14:39.298Z","updated_at":"2024-07-02T16:35:26.861Z","phase":"Phase 2","brief_title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","source_id_and_acronym":"NCT06121271","lead_sponsor":"University College, London","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 11/06/2027","primary_completion_date":" 11/06/2027","study_txt":" Completion: 11/06/2027","study_completion_date":" 11/06/2027","last_update_posted":"2023-12-07"},{"id":"fcef40a5-c577-44fe-8d9f-710714f59f23","acronym":"","url":"https://clinicaltrials.gov/study/NCT04524442","created_at":"2021-02-11T16:55:19.967Z","updated_at":"2024-07-02T16:35:26.999Z","phase":"Phase 4","brief_title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","source_id_and_acronym":"NCT04524442","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 11/18/2023","primary_completion_date":" 11/18/2023","study_txt":" Completion: 11/18/2023","study_completion_date":" 11/18/2023","last_update_posted":"2023-12-05"},{"id":"01ee014a-7d08-4da3-a0a3-f28ad90c284a","acronym":"COMPETE","url":"https://clinicaltrials.gov/study/NCT03049189","created_at":"2021-01-18T15:00:56.649Z","updated_at":"2024-07-02T16:35:27.442Z","phase":"Phase 3","brief_title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","source_id_and_acronym":"NCT03049189 - COMPETE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-11-30"},{"id":"655df006-f3b7-40a3-bc87-b9058d866bb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457948","created_at":"2021-01-19T15:39:53.519Z","updated_at":"2025-02-25T16:07:39.992Z","phase":"Phase 2","brief_title":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases","source_id_and_acronym":"NCT03457948","lead_sponsor":"Nicholas Fidelman, MD","biomarkers":" PD-L1 • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["PD-L1 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-11-17"},{"id":"d35bf2f8-c72c-4e41-b03f-2a4b88237830","acronym":"LuPARP","url":"https://clinicaltrials.gov/study/NCT04375267","created_at":"2021-01-18T21:08:12.416Z","updated_at":"2025-02-25T15:43:58.882Z","phase":"Phase 1","brief_title":"177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours","source_id_and_acronym":"NCT04375267 - LuPARP","lead_sponsor":"Vastra Gotaland Region","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-11-14"}]